ATLANTA — The soaring popularity of GLP-1 weight-loss drugs has helped millions of people lose weight, but the cost of the medications is leading some consumers to seek cheaper, unapproved alternatives online.
Georgia Poison Center officials say calls involving GLP-1 drugs have surged, and some patients are ending up in emergency rooms after dosing errors. Over the past two years, about one in five GLP-1 calls to the center involved unapproved drugs sold on what is often called the “gray market,” according to the center’s executive director, Dr. Gaylord Lopez.
Hayley Lithwick said GLP-1 medications changed her life.
“I was over 300 pounds before, and it really helped me a lot to lose a lot of weight and gain confidence,” Lithwick said.
Lithwick said she had struggled with her weight all her life. After talking with a doctor, she began taking Zepbound, an FDA-approved prescription medication. She said the drug reduced her appetite, and she started exercising more.
But after a job change, Lithwick lost her insurance coverage for the medication and could no longer afford it.
“I was gaining a lot of weight back,” she said.
Looking for another option, Lithwick went online and purchased retatrutide, an investigational drug that is still being studied in clinical trials.
The website Lithwick used included a warning that the product was “not for human or veterinary use, consumption, or application.”
Still, Lithwick said she paid about $200 for what she believed would be a month’s supply.
What arrived was not a ready-to-use medication. It was powder in vials.
“I was so confused. I was like, ‘What is this?’” she said.
MORE CHANNEL 2 ACTION NEWS INVESTIGATES STORIES:
- When pets are lost or die at Georgia kennels, their histories can be hard to find
- Amazon, Microsoft and Google pledge more transparency on data center after NDA concerns
- BioLab fire exposed chemical risks. Now some federal safety rules could be rolled back
- GLP-1 drugs will now have warning label about potential increased risk of blindness
Lithwick said she was uncomfortable with what she received but felt she had few affordable alternatives.
“I was very sketched out, but I kind of felt that there wasn’t really a choice,” she said.
She turned to the internet for instructions on how to mix the powder herself, a step that can introduce additional risks when performed outside of a sterile pharmacy environment.
Then she became sick.
“I was sweating a lot. I had nausea, an upset stomach,” Lithwick said. “I was just feeling really, really sick**,** and my heart was beating really, really fast, and I wanted to go to the hospital.”
Lithwick later determined that she had likely given herself about twice the intended dose.
Lopez said Lithwick’s experience highlights one of the problems the Georgia Poison Center is seeing as demand for GLP-1 medications grows.
“They’re confusing milligrams with milliliters,” Dr. Lopez said. “They may be using insulin syringes.”
Unapproved products that consumers have to mix themselves can present another risk.
“Certainly, you run the risk of higher infection rates because you’re not working in sterile environments,” Lopez said.
The problem is not limited to unapproved products.
The Georgia Poison Center received 38 calls involving GLP-1 drugs in 2021. So far in 2026, that number has climbed to 655, according to Dr. Lopez.
That amounts to about a 1,600% increase.
Dr. Lopez said about 15% of the people who call the poison center about GLP-1 drugs end up needing evaluation in an emergency room.
“They’re running into issues like prolonged vomiting, excessive vomiting, and these start just a chain of other reactions,” Dr. Lopez said. “Once you start losing body fluid, you start having other problems.”
Severe vomiting can lead to dehydration and other complications.
Eli Lilly is developing retatrutide, the drug Lithwick said she purchased online. The drug is in Phase 3 clinical trials and is not currently approved for public use.
The company has warned that retatrutide is not yet available for public use and that no one can legally sell the drug for human use while it remains an investigational medication.
Despite her frightening experience with the unapproved product, Lithwick said GLP-1 medications have had a profound impact on her life. She said she has lost about 200 pounds overall.
“I feel a lot better now than what I felt before, that’s for sure,” she said.
©2026 Cox Media Group





